 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management...

Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Anika Therapeutics, Inc. (NASDAQ:ANIK - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Short Interest Update

Anika Therapeutics, Inc. (NASDAQ:ANIK - Get Free Report) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $22.02...

Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving Average of $22.02

This is a signal that ANIK's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Anika Therapeutics (ANIK, $25.61) Stochastic Oscillator left the overbought zone on March 20, 2024

Q4 2023 Anika Therapeutics Inc Earnings Call Transcript

Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript...

Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript

Anika Therapeutics: Q4 Earnings Insights

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Anika Therapeutics to reduce 9% of workforce in cost reduction initiative

Anika Therapeutics sees FY24 revenue $168M-$173M, consensus $179.42M

Anika Therapeutics reports Q4 adjusted EPS 5c, consensus (26c)

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

Volume (M)	6,652.00
52-Wk High	$28.13
52-Wk Low	$16.54

ANIK Anika Therapeutics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals